Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court
This article was originally published in The Pink Sheet Daily
Executive Summary
The appellate judges decline to rule on the validity of FDA’s patent-by-patent approach to awarding generic marketing exclusivity in either case. Apotex’ challenge to Purepac’s gabapentin exclusivity is barred by earlier litigation, court says; FDA’s appeal stemming from paroxetine exclusivity ruling is dismissed as moot.
You may also be interested in...
Barr Is Latest Generic Firm To Challenge FDA’s Patent-Based Exclusivity Policy
In a D.C. federal court lawsuit, Barr asserts it was the first applicant to file a Paragraph IV certification against any “Orange Book” listed patent for Allegra-D. Consequently, the company says, it should not have to share 180-day generic marketing rights with Impax.
Barr Is Latest Generic Firm To Challenge FDA’s Patent-Based Exclusivity Policy
In a D.C. federal court lawsuit, Barr asserts it was the first applicant to file a Paragraph IV certification against any “Orange Book” listed patent for Allegra-D. Consequently, the company says, it should not have to share 180-day generic marketing rights with Impax.
FDA's Patent-Based ANDA Exclusivity Policy Challenged By Apotex
Apotex files suit to force approval of its Prilosec ANDA, which is being held up by Andrx' exclusivity. Suit charges that FDA improperly granted Andrx additional period of exclusivity for omeprazole 40 mg based on a late-filed patent.